Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley Sells 10,000 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Exelixis Trading Up 1.0 %

Shares of NASDAQ EXEL opened at $38.58 on Friday. The firm’s 50-day moving average price is $34.90 and its 200-day moving average price is $31.96. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $39.30. The firm has a market capitalization of $10.80 billion, a P/E ratio of 21.80, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Ratings Changes

EXEL has been the topic of a number of recent analyst reports. Brookline Capital Management initiated coverage on Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating on the stock. JMP Securities restated a “market outperform” rating and set a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. Guggenheim reissued a “buy” rating and issued a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Finally, BMO Capital Markets downgraded Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $36.00 to $40.00 in a report on Friday, December 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.24.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Coppell Advisory Solutions LLC bought a new position in Exelixis in the 4th quarter worth approximately $25,000. Colonial Trust Co SC raised its position in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 765 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of Exelixis during the 4th quarter valued at $32,000. Principal Securities Inc. raised its position in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares in the last quarter. Finally, Kestra Investment Management LLC purchased a new position in Exelixis in the 4th quarter worth $39,000. 85.27% of the stock is owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.